8-KLeadership ChangesRegulation FDExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jan 4, 2022)

Filed January 4, 2022For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant leadership update via an 8-K filing on January 4, 2022. The most notable change is the appointment of Dr. Akshay K. Vaishnaw as President, effective January 1, 2022. Dr. Vaishnaw, previously the President of Research and Development, brings extensive experience within Alnylam, having held various leadership roles since 2006, and has also served in leadership at Biogen. This promotion follows the prior announcement of Yvonne L. Greenstreet's appointment as CEO. In conjunction with his new role, Dr. Vaishnaw will receive an updated compensation package, including an annual base salary of $725,000, a target bonus of 60% of his base salary, and a significant stock option grant valued at $2,000,000. This grant vests over four years, aligning his incentives with long-term company performance. Investors should view this as a move to solidify the senior leadership team and acknowledge Dr. Vaishnaw's continued contributions to the company's R&D efforts as it transitions to a new CEO.

Key Highlights

  • 1Akshay K. Vaishnaw, M.D., Ph.D., appointed as President, effective January 1, 2022.
  • 2Dr. Vaishnaw has a long tenure at Alnylam, holding various R&D and clinical leadership positions since 2006.
  • 3This appointment follows the recent naming of Yvonne L. Greenstreet as CEO.
  • 4Dr. Vaishnaw's annual base salary will be $725,000.
  • 5He will have a target bonus of 60% of his base salary for the 2022 performance year.
  • 6Dr. Vaishnaw received a stock option grant with a fair value of $2,000,000, vesting over four years.
  • 7The company issued a press release on January 4, 2022, to announce this promotion.

Frequently Asked Questions

Dr. Vaishnaw's promotion to President solidifies the senior leadership team at Alnylam, particularly in the context of the recent CEO transition. It recognizes his extensive experience in Research and Development, a critical area for a biopharmaceutical company, and aligns his role with the overall operational leadership.

Dr. Vaishnaw's compensation includes an annual base salary of $725,000 and a target bonus of 60% of his base salary for the 2022 performance year. Additionally, he was granted stock options valued at $2,000,000, which vest over four years, demonstrating a commitment to long-term value creation and employee retention.

The stock options granted to Dr. Vaishnaw vest over a four-year period. 25% of the award vests on the first anniversary of the grant date (December 31, 2021), with an additional 6.25% vesting at the end of each subsequent three-month period until the fourth anniversary of the grant date.

Yes, Dr. Vaishnaw has a long history with Alnylam, serving in various senior R&D and clinical roles since January 2006, including President of Research and Development, Executive Vice President of Research and Development, and Chief Medical Officer. Prior to Alnylam, he held positions at Biogen Inc., including Senior Director of Translational Medicine.